Gan Huachen, McKenzie Raymond, Hao Qin, Idell Steven, Tang Hua
Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, Texas, United States of America.
Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, Texas, United States of America; Texas Lung Injury Institute, The University of Texas Health Science Center at Tyler, Tyler, Texas, United States of America.
PLoS One. 2014 Jul 7;9(7):e101983. doi: 10.1371/journal.pone.0101983. eCollection 2014.
Idiopathic pulmonary fibrosis (IPF) is a relentlessly progressive and usually fatal lung disease of unknown etiology for which no effective treatments currently exist. Hence, there is a profound need for the identification of novel drugable targets to develop more specific and efficacious therapeutic intervention in IPF. In this study, we performed immunohistochemical analyses to assess the cell type-specific expression and activation of protein kinase D (PKD) family kinases in normal and IPF lung tissue sections. We also analyzed PKD activation and function in human lung epithelial cells. We found that PKD family kinases (PKD1, PKD2 and PKD3) were increased and activated in the hyperplastic and regenerative alveolar epithelial cells lining remodeled fibrotic alveolar septa and/or fibroblast foci in IPF lungs compared with normal controls. We also found that PKD family kinases were increased and activated in alveolar macrophages, bronchiolar epithelium, and honeycomb cysts in IPF lungs. Interestingly, PKD1 was highly expressed and activated in the cilia of IPF bronchiolar epithelial cells, while PKD2 and PKD3 were expressed in the cell cytoplasm and nuclei. In contrast, PKD family kinases were not apparently increased and activated in IPF fibroblasts or myofibroblasts. We lastly found that PKD was predominantly activated by poly-L-arginine, lysophosphatidic acid and thrombin in human lung epithelial cells and that PKD promoted epithelial barrier dysfunction. These findings suggest that PKD may participate in the pathogenesis of IPF and may be a novel target for therapeutic intervention in this disease.
特发性肺纤维化(IPF)是一种病因不明、病情持续进展且通常致命的肺部疾病,目前尚无有效的治疗方法。因此,迫切需要鉴定新的可成药靶点,以便在IPF中开发更具特异性和有效性的治疗干预措施。在本研究中,我们进行了免疫组织化学分析,以评估正常和IPF肺组织切片中蛋白激酶D(PKD)家族激酶的细胞类型特异性表达和激活情况。我们还分析了PKD在人肺上皮细胞中的激活和功能。我们发现,与正常对照相比,PKD家族激酶(PKD1、PKD2和PKD3)在IPF肺中重塑的纤维化肺泡间隔和/或成纤维细胞灶内衬的增生性和再生性肺泡上皮细胞中增加并被激活。我们还发现,PKD家族激酶在IPF肺中的肺泡巨噬细胞、细支气管上皮和蜂窝状囊肿中增加并被激活。有趣的是,PKD1在IPF细支气管上皮细胞的纤毛中高表达并被激活,而PKD2和PKD3在细胞质和细胞核中表达。相比之下,PKD家族激酶在IPF成纤维细胞或肌成纤维细胞中未见明显增加和激活。我们最后发现,PKD在人肺上皮细胞中主要被聚-L-精氨酸、溶血磷脂酸和凝血酶激活,并且PKD促进上皮屏障功能障碍。这些发现表明,PKD可能参与IPF的发病机制,并且可能是该疾病治疗干预的新靶点。